Biosense Webster, Inc. Announces Two Panel Symposia and Three Poster Presentations at Heart Rhythm Society's 37th Annual Scientific Sessions

DIAMOND BAR, Calif., May 3, 2016 /PRNewswire/ -- Biosense Webster, Inc. will host two panel symposia and present data in three poster presentations at the Heart Rhythm Society's (HRS) 37th Annual Scientific Sessions, being held May 4-7, 2016 in San Francisco, California.

The two symposia, being held in the conference exhibit hall, will feature key opinion leaders presenting on treatment of paroxysmal atrial fibrillation (PAF), including ablation with contact force technology. The three poster sessions will present data on radiofrequency (RF) catheter ablation, including a featured poster comparing the costs of RF catheter ablation versus cryoablation.

Panelists and poster authors (listed below) will be available for interviews before and during the meeting.

Hosted Symposia
My Reality: A 2-Hour PAF Ablation with Contact Force Technology

Date/Time: Wednesday, May 4 from 12:30 – 1:30 pm
Location: Rhythm Theatre I – Booth 129, Exhibit Hall
Panelists:

• Oussama Wazni, MD, MBA, FACC, FHRS, Co-director of the Atrial Fibrillation and Ventricular Arrhythmia Centers, Cleveland Clinic, Cleveland, Ohio
• Jose Osorio, MD, FACC, FHRS, Grandview Health Center, Birmingham, Alabama
• Andrew Brenyo, MD, FACC, FHRS, Greenville Health System, Greenville, South Carolina

Voltage Validation in PAF Procedures: Where to Draw the Line
A Multimedia-Based Clinical Discussion on the Utility of High-Density Voltage Mapping in PAF Procedures

Date/Time: Friday, May 6 from 3:15 – 4:15 pm
Location: Rhythm Theatre 2 – Booth 2429, Exhibit Hall
Panelists:

• Brett Gidney, MD, FACC, FHRS, Heart Rhythm Center, Santa Barbara, California
• Raman Mitra, MD, PhD, Medical Director, Cardiology and Cardiac Electrophysiology Memorial Hospital, Beacon Health System, South Bend, Indiana
• Tariq Salam, MD, FACC, FHRS, Medical Director, Heart Rhythm Service, Multicare Health System, Cardiac Study Center, Tacoma, Washington

Posters
Featured Poster: Cost Comparison of Radiofrequency (RF) Catheter Ablation vs. Cryoablation for Atrial Fibrillation in Hospitals Using Both Technologies
Author: Tina Hunter, PhD
Date/Time: Wednesday, May 4 from 5 – 7 pm
Key Findings: The report finds significantly lower costs for RF ablation of atrial fibrillation compared with cryoablation, despite the RF use in patients with more cardiovascular disease.

Relationship of Contact Force and its Stability with Optimal Long-Term Success in the SMART AF Trial
Author: Vivek Reddy, MD
Time/Date: Friday, May 6 from 9 am – 12 pm
Key Findings: The report, which looks at the THERMOCOOL SMARTTOUCH^® Catheter for atrial fibrillation, describes the importance of contact force stability in optimizing long-term clinical outcomes.

Stability of Contact Force Correlates with Long-Term Success in PAF RFA: Experience from THERMOCOOL SMARTTOUCH^® Catheter Registry
Author: Tom DePotter, MD
Time/Date: Friday, May 6 from 2 – 5 pm
Key Findings: The report, which looks at the THERMOCOOL SMARTTOUCH^® Catheter for atrial fibrillation, describes the importance of contact force stability in optimizing long-term clinical outcomes.

About Atrial Fibrillation and Catheter Ablation
Atrial fibrillation (Afib) is the most prevalent heart rhythm disorder and a leading cause of stroke among people 65 years and older. An estimated 3 million people in the United States and 20 million worldwide are affected by Afib, and its prevalence is projected to increase significantly as the population ages.¹ Afib is a progressive disease and increases in severity and frequency as patients get older. Left untreated, it can lead to heart valve disease, sleep apnea, chronic fatigue, congestive heart failure and stroke. The public health implications of Afib are a growing concern because those with Afib are at an increased risk of morbidity and mortality, as well as a reduced quality of life. It is estimated to be responsible for more than 80,000 deaths and range from $6 to $26 billion in incremental costs to the U.S. healthcare system on an annual basis.²

During catheter ablation, doctors insert a therapeutic catheter through a small incision in the groin, where it is then weaved up to the heart through a blood vessel. Once it reaches the left upper chamber of the heart (atrium), radiofrequency energy is delivered to the heart wall to create lesions that block faulty electrical impulses that can cause heart rhythm disorders.

About Biosense Webster, Inc.
Biosense Webster, Inc. is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. Biosense Webster is part of the Johnson & Johnson Family of Companies. More information can be found on www.biosensewebster.com.

THERMOCOOL^® Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO^® Systems (excluding NAVISTAR® RMT THERMOCOOL^® Catheter).

Always verify catheter tip location using fluoroscopy or IC signals and consult the CARTO^® System User Guide regarding recommendations for fluoroscopy use.¹

Always make sure to have a primary and secondary imaging source (e.g., the CARTO^® System and an ultrasound system) and retain the ability to verify catheter tip location with fluoroscopy if needed.

Caution:  US law restricts this device to sale by or on the order of a physician. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.

¹ Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol.2009;104:1534-1539.
² Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313–320.25
³Sporton S et al. Journal of Cardiovascular Electrophysiology 2004;15,3:310-315.

Logo - http://photos.prnewswire.com/prnh/20160502/362691LOGO

SOURCE Biosense Webster, Inc.

Related Links

http://www.biosensewebster.com